Anupam Rasayan India Limited (ANURAS)
🎯 Key Takeaways
- Anupam Rasayan India Limited is transitioning from a mature chemical manufacturer into an actively consolidating player in the pharma CDMO space, marked by its aggressive acquisition strategy targeting Bliss GVS Pharma. The company is in a strategic investment phase, leveraging strong revenue growth to fund expansion into high-margin contract development and manufacturing services, particularly in regulated markets like the U.
- Revenue grew 24.1% QoQ to ₹636 in Q4FY26.
- ⚠️ 1) Integration risk from acquiring Bliss GVS Pharma, with synergies expected only within 6-18 months and potential disruption to ongoing operations. 2
📖 The Story
Anupam Rasayan India Limited is transitioning from a mature chemical manufacturer into an actively consolidating player in the pharma CDMO space, marked by its aggressive acquisition strategy targeting Bliss GVS Pharma. The company is in a strategic investment phase, leveraging strong revenue growth to fund expansion into high-margin contract development and manufacturing services, particularly in regulated markets like the U.S. and Europe.
📰 What's Happening
Management has been executing a clear inorganic growth strategy, finalizing a definitive agreement to acquire a 43.3%-48.2% stake in Bliss GVS Pharma and launching a mandatory open offer to acquire an additional 26% stake at ₹299 per share. The offer, backed by ₹3,038 crore of available resources and ₹160 crore escrow, aims to build a 74.2% total holding. Integration plans focus on synergies in CDMO capabilities across India, the U.S., and Europe, with pro forma revenue targeted at ₹4,000 crores and 20-30% CAGR over 3-5 years. Crisil has upgraded debt ratings but placed them on Watch Developing due to leverage from the acquisition.
Source: Stock Announcements
📊 Quarterly Results (₹ Cr)
| Metric | Q1FY25 | Q2FY25 | Q3FY25 | Q4FY25 | Q1FY26 | Q2FY26 | Q3FY26 | Q4FY26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 254 | 294 | 390 | 500 | 486 | 731 | 512 | 636 |
| Operating Profit | 59 | 82 | 121 | 150 | 129 | 144 | 130 | 141 |
| OPM % | 20.9% | 27.4% | 31.9% | 28.9% | 25.6% | 18.6% | 24.9% | 21.6% |
| Net Profit | 12 | 31 | 54 | 63 | 48 | 57 | 61 | 56 |
| EPS | ₹0.36 | ₹1.51 | ₹2.57 | ₹4.06 | ₹3.10 | ₹3.93 | ₹4.31 | ₹3.75 |
Revenue growth has accelerated significantly, rising from ₹254 crores in Q1FY25 to ₹636 crores in Q4FY26, with FY26 revenue reaching a record ₹2,384 crores as per the latest filing. However, operating margins have declined from 28.9% in Q4FY25 to 21.6% in Q4FY26, reflecting the operational drag of scaling up under the acquisition and integration phase. Net profit trends show volatility, peaking at ₹63 crores in Q4FY25 but declining to ₹56 crores in Q4FY26, suggesting margin pressure is emerging despite top-line expansion.
🔮 Management Outlook & What's Next
Management explicitly targets a 20-30% CAGR over the next 3-5 years post-acquisition, driven by expansion of CDMO capabilities in key geographies and synergy realization within 6-18 months. They emphasize maintaining independent operations post-acquisition while leveraging Bliss GVS Pharma’s existing infrastructure to scale high-growth segments. The open offer is framed as a strategic step to achieve full control and accelerate integration, with no indication of dividend policy changes despite strong cash flows.
Extracted from official company announcements. Not StockFin.ai's opinion.
🏦 Balance Sheet (₹ Cr)
| Item | 2024-2025 | 2025-2026 | 2025-2026 | 2025-2026 | 2025-2026 |
|---|---|---|---|---|---|
| Equity Capital | 110 | 110 | 114 | 114 | 146 |
| Reserves | 2,740 | — | 3,083 | — | 3,188 |
| Borrowings | 1,318 | — | 1,170 | — | 1,815 |
| Total Liabilities | 2,187 | — | 2,201 | — | 3,383 |
| Fixed Assets | 2,038 | — | 2,276 | — | 2,980 |
| Investments | 9 | — | 9 | — | 19 |
| Total Assets | 5,269 | — | 5,650 | — | 8,013 |
The balance sheet shows a significant increase in borrowings to ₹1,815 crores and equity to ₹146 crores (including reserves of ₹3,188 crores), reflecting capital-intensive growth through debt and equity funding. The acquisition is being financed through a mix of internal resources (₹3,038 crores available) and external debt, with Crisil placing debt ratings on Watch Developing due to leverage concerns. Despite asset growth to ₹8,013 crores, the rising debt-to-equity ratio and working capital intensity pose near-term financial flexibility challenges.
💰 Cash Flow Statement (₹ Cr)
| Item | 2020-2021 |
|---|---|
| Operating | +1 |
| Investing | -193 |
| Financing | +416 |
| Net Cash Flow | — |
⚖️ Peer Comparison — Chemicals & Petrochemicals
| Company | MCap (₹ Cr) | P/E | ROCE | ROE | D/E |
|---|---|---|---|---|---|
| Solar Industries India Limited | 1.57 L Cr | 132.3 | — | — | — |
| Pidilite Industries Limited | 1.49 L Cr | 75.7 | — | — | — |
| SRF Limited | 79,723 | 69.5 | — | — | — |
| Linde India Limited | 62,701 | 141.9 | — | — | — |
| Gujarat Fluorochemicals Limited | 40,793 | 89.6 | — | — | — |
| Navin Fluorine International Limited | 35,894 | 131.5 | — | — | — |
| Himadri Speciality Chemical Limited | 30,071 | 56.6 | — | — | — |
| Deepak Nitrite Limited | 24,911 | 33.3 | — | — | — |
| Atul Limited | 20,904 | 48.8 | — | — | — |
| Tata Chemicals Limited | 19,079 | -47.1 | — | — | — |
🔗 Peer Stock Analyses
⚠️ Risk Factors
1) Integration risk from acquiring Bliss GVS Pharma, with synergies expected only within 6-18 months and potential disruption to ongoing operations. 2) Margin pressure persists despite revenue growth, with OPM declining to 21.6% in Q4FY26 from 28.9% a year ago, partly due to the operational scale-up. 3) High leverage post-acquisition, with Crisil placing debt on Watch Developing due to working capital intensity and foreign exchange volatility. 4) Market acceptance risk of the open offer price of ₹299 per share, which may not reflect a premium or may face shareholder resistance.
📋 Recent Filings
-
🔴 offer document 21 July 2026Anupam Rasayan India Limited (ANURAS) announced that it, along with its wholly owned subsidiary Mates Visa Consultancy Private Limited (PAC), is makin...
-
Announcement 17 July 2026Anupam Rasayan India Limited announced it has completed the acquisition of 100% of Mates Visa Consultancy Private Limited for INR 10,000 cash consider...
-
Announcement 15 July 2026Anupam Rasayan India Limited announced it signed a non-binding Letter of Intent with BASQUEVOLT, S.A. to explore a potential long-term supply of a spe...
-
Financial Results 25 June 2026Anupam Rasayan India Limited announced that its trading window will close from July 1, 2026 until 48 hours after the unaudited financial results for t...
-
Announcement 11 June 2026Anupam Rasayan India Limited announced on June 11, 2026 that it has become the first company globally to commercialize ETFA (Ethyl trifluoroacetate) u...
-
regulation 31 9 June 2026Kiran Pallavi Investments LLC, promoter of Anupam Rasayan India Limited, filed a mandatory SEBI disclosure under Regulation 31(4) for the financial ye...
-
🔴 offer document 9 June 2026Anupam Rasayan India Limited announced that SBI Capital Markets has filed a Draft Letter of Offer with SEBI for a mandatory open offer to acquire up t...
-
🔴 Announcement 3 June 2026Anupam Rasayan India Limited announced that Crisil Ratings upgraded its bank loan facilities to Rs. 1620 crore (from Rs. 1369.82 crore) and assigned a...
-
🔴 Financial Results 30 May 2026Anupam Rasayan India reported record revenue of **₹2,384 crores** in FY26, driven by growth in high-performance materials and pharma segments, with EB...
-
🟡 Board Meeting 23 May 2026The Board approved FY2026 audited results showing INR 16,755.30 million revenue and INR 1,613.96 million PAT, recommended a final dividend of INR 1.5 ...
🧠 Analyst's Read
Anupam Rasayan is executing a high-stakes transformation, betting on consolidation to enter the high-growth CDMO space. Success hinges on timely integration of Bliss GVS Pharma, margin recovery, and debt management. Investors should monitor the open offer outcome, synergy realization pace, and quarterly margin trends as early indicators of execution quality.
Based on filing content and financial data. Not a recommendation.
Read the full analysis
Quarterly trends, balance sheet, cash flow, peer comparison, and AI insights — sign up free to unlock.
Sign Up Free — Unlock Full Analysis2 free AI queries per day.
Data sourced from stock announcements. Analysis generated by StockFin.ai.
For informational purposes only — not investment advice. Updated 2026-07-24.
📡 Get AI alerts when ANURAS files new disclosures
Track ANURAS filings, board meetings, and corporate actions. Free email alerts at 5 PM.
Track ANURAS — FreeFree account · 2 AI queries/day
© 2026 StockFin.ai — AI-powered Indian stock research